Fig. 4.

Effects of nuclear receptor agonist treatments on extracellular matrix gene expression in chondrocytes. IMACs were incubated for 72 h with 1 μM DMSO (vehicle control), PPARδ agonist GW501516, PPARγ agonist Rosiglitazone, LXR agonist GW3965, or RXR agonist SR11237. a Relative gene expression of Acan gene is significantly reduced by treatment with the RXR agonist. b, c Relative gene expression of Adamts4 and Fbn2 are significantly reduced by LXR and RXR agonist treatment. d, e Relative gene expression of matrix metalloproteinases Mmp2 and Mmp13 is decreased by LXR agonist treatment, while gene expression of Mmp13 is significantly elevated by RXR agonist treatment. f Col2a1 gene expression remains unchanged by all treatments. Values represented are the mean ± SEM of ≥3 independent cell isolations. *p < 0.05